Allergan's still okay with holding a special shareholder meeting on Dec. 18, a date it last month agreed on with wannabe acquirer Valeant. It just doesn't want its pursuer's partner, Bill Ackman, to have a say.
Hyperion Therapeutics, which claims it was duped into a $570 million deal for an Israeli biotech, has reached a temporary agreement with the seller, calling off its lawyers for the moment while the two try to determine whether the drug at the heart of the acquisition has any future.
Teva and Mylan merge? Rumors are certainly swirling--and not for the first time, either. But while a potential deal might make financial sense, at least one analyst doesn't see it happening.
Buyout-hungry Actavis--which is alternatively spotlighted as both a buyer and a possible buyout target--has snapped up Chicago-based Durata Therapeutics and its recently approved antibiotic Dalvance (dalbavancin) for $675 million plus a potential bonus.
CRO Chiltern has reached into Singapore for its latest acquisition, buying out an Asian clinical contractor to expand its geographic footprint and therapeutic reach.
In its first acquisition since going public over the summer, Catalent has bought up longtime partner Redwood Bioscience, bringing in proprietary technology for developing antibody-drug conjugates.
Neogen, the maker of food and animal safety products, acquired Ann Arbor, MI-based BioLumix through a purchase of all of the company's outstanding stock.
Inversion mania seems to be dying down, but med tech merger mania continues. In the latest development, Becton Dickinson announced over the weekend that it will acquire Carefusion for $12.2 billion in a bid to save costs and broaden the company's offerings to hospitals.
Chinese CRO WuXi PharmaTech has bought out XenoBiotic Laboratories, a U.S. contractor focused on early-phase research, expanding its North American presence and broadening its lab-based business.
Parexel International has bought up the U.K.'s ClinIntel, a supply chain software outfit that should fit right in with the CRO's growing technology business.